Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Alector Opts for Lonza's Ibex™ Develop to Secure Future Manufacturing for Neurodegeneration Therapies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 05:28pm EDT
  • Alector and Lonza Pharma & Biotech extend their partnership to cover future manufacturing needs of two of Alector's clinical stage product candidates
  • Access to Lonza's expertise in expedited programs and BLA filings will accelerate Alector's market readiness

Quote from Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech:

'Ibex Develop was launched in 2018, with the goal of giving our customers access to technology and assets in sync with their journey, as well as the agility to respond as their needs develop. With biotech customers like Alector who want to commercialize their drug candidate, we offer a rapid and simplified path to transition from clinical to launch which allows them to focus on bringing their therapies to patients.'

Quote from Robert King, Chief Development Officer, Alector:

'Lonza continues to be an innovator in the space and their flexible solutions and product offerings enable Alector to focus on drug development and bringing therapeutics to market to address the severe unmet need in neurodegeneration as efficiently as possible. Lonza's considerable knowledge and experience make them an attractive long-term partner.'

San Francisco, USA and Basel, Switzerland, 2 May 2019 - Alector (NASDAQ:ALEC) and Lonza (SWX:LONN) announced an agreement to secure manufacturing capacity for two of Alector's drug candidates currently in Phase 1 development for neurodegenerative diseases. The California-based biotech chose Lonza's IbexTM Solutions to ensure drug supply and accelerate market-readiness.

The two companies have been working together since 2016 on the early phases of development for Alector's lead candidates. Based on the potential product needs of these candidates, Lonza's GS Xceed® Gene Expression System was used to create high-producing cell lines. The programs have also included clinical manufacturing of drug substance and drug product across the Lonza network. Alector is now looking to secure supply for current and future trials with the ability to scale up rapidly.

The Ibex Develop offering in Visp, Switzerland was a compelling choice for Alector, who was looking for a simplified tech transfer from Lonza's clinical assets in Slough (UK) and Hayward, CA (US) into a scalable solution with clinical and commercial production under the same roof. Under the agreement, Alector will have the flexibility to move molecules from their pipeline in and out of production as needed, to match the pace of their clinical trials and assure the quantities required are available. Ibex Develop is based on flexible single-use technology that allows management of forecast volatility and scale-up or -out within the same facility or in the wider Lonza network.

In addition, Alector will be able to leverage Lonza's experience in expedited regulatory pathways and in bringing biologics successfully through BLA submissions as well as the option of drug substance and drug product manufacturing under one roof.

The Visp, CH facility, from which Ibex Solutions is offered, will be operational from 2020 onward, with planned start of operations for Alector in Q3 2020.

Disclaimer

Lonza Group Ltd. published this content on 02 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 May 2019 21:27:14 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
06:17pLONZA : Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of M..
AQ
10/15GENMAB : Lonza's Ibex Solutions to Support Genmab's Growing Clinical Portfolio
AQ
10/08PREVAIL THERAPEUTICS : and Lonza Establish Strategic Collaboration to Develop an..
AQ
10/08TRACKINSIGHT : Performance boost from Swiss Stocks
TI
10/04LONZA : MODA-ES TM Platform helps Nephron Pharmaceuticals move from paper to an ..
AQ
10/02CELLECTIS : and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis :..
AQ
09/24LONZA : Launches Joint Health Consumer Education Campaign with New York Photogra..
AQ
09/10LONZA : Announces Refinancing Extension and Increase of Its Term and Revolving B..
AQ
09/10LONZA : Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiti..
AQ
09/03CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
More news
Financials (CHF)
Sales 2019 5 908 M
EBIT 2019 1 209 M
Net income 2019 736 M
Debt 2019 3 244 M
Yield 2019 0,84%
P/E ratio 2019 34,6x
P/E ratio 2020 28,9x
EV / Sales2019 4,82x
EV / Sales2020 4,46x
Capitalization 25 236 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 373,42  CHF
Last Close Price 339,90  CHF
Spread / Highest target 35,9%
Spread / Average Target 9,86%
Spread / Lowest Target -19,1%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP32.94%25 190
IQVIA HOLDINGS INC.26.16%28 710
CELLTRION, INC.--.--%19 786
INCYTE CORPORATION23.48%16 887
SEATTLE GENETICS, INC.47.16%14 169
EXACT SCIENCES CORPORATION58.07%12 915